The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes
Open accessThe DOI matches its Crossref record.
Abstract
It is well known that C-peptide fulfills an important function in the synthesis of insulin. After cleavage of proinsulin in the pancreatic β-cells, the 31-amino acid C-peptide is secreted into the portal circulation in equimolar concentrations with insulin. After its discovery in 1967 (1), it was believed that C-peptide might exert physiological effects similar to those of insulin. However, no influence on glucose or lipid metabolism could be demonstrated, and C-peptide was subsequently regarded as a waste product of insulin synthesis. Nevertheless, it was found to be useful as an indicator of β-cell function, and since the mid-1970s, C-peptide has been used as a surrogate marker for monitoring the course of type 1 and type 2 diabetes and determining the effects of interventions designed to preserve and improve residual β-cell function. Several studies demonstrate that patients with type 1 diabetes who show a degree of remaining β-cell activity are considerably less prone to develop microvascular complications than those who are totally C-peptide deficient (2). The possibility that C-peptide may exert direct effects of its own was reevaluated in the early 1990s. A series of studies was undertaken involving administration of the peptide to patients with type 1 diabetes, who lack C-peptide. This approach gave positive results, and it became apparent that replacement of C-peptide in physiological concentrations resulted in significant improvements in several diabetes-induced functional abnormalities (3–7). These surprising findings prompted a renewed interest in C-peptide physiology, and during the past 15 years, a steadily increasing number of reports on new aspects of C-peptide physiology have emerged. The information available today includes studies of the peptide’s interaction with cell membranes and its intracellular signaling properties (8). In vivo studies in animal models of type 1 diabetes have defined a beneficial influence of C-peptide on diabetes-induced functional and structural …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
The clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628
Lehmann, R., Graziano, J., Brockmann, J., Pfammatter, T., Kron, P., de Rougemont, O., Mueller, T., Zuellig, R. A., Spinas, G. A., & Gerber, P. A. (2015) · Diabetes Care · doi:10.2337/dc14-1686 · Cited by 94
Iqbal, S., Jayyab, A. A., Alrashdi, A. M., & Reverté-Villarroya, S. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.01.004 · Cited by 27
Metadata
- Authors
- Wahren, J., Kallas, Å., & Sima, A. A. F.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-03-14
- Volume
- 61
- Issue
- 4
- Pages
- 761-772
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2143255381
- Cited by
- 150
- References
- 0
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/db11-1423
- The paper
- Wahren, J., Kallas, Å., & Sima, A. A. F. (2012). The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes. Diabetes. https://doi.org/10.2337/db11-1423
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.